AUG 21·SEC EDGARLow
Jones Keith Anthony purchased $7K of HUMA
Jones Keith Anthony purchased 10,000 shares of Humacyte, Inc. (HUMA) at $0.69 on 2026-08-20.
StockNASDAQ · US · USDHealthcare · Biotechnology
$HUMA
Humacyte, Inc.
alphai earnings readSecond Quarter 2026 · AUG 12Humacyte Announces Second Quarter 2026 Financial Results and Provides Business UpdateVerdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $HUMAvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $HUMA in the last 7 days.
Insider · 30dAll trades →
- Buys
- $25K 2 txs
- Sells
- — 0 txs
Jones Keith Anthony2× · $25K
10b5-1 share of filings0%
Top stories · $HUMAMore →
AUG 21·rttnews.com
Weekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks
Ultragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
AUG 19·SEC EDGAR
Jones Keith Anthony purchased $18K of HUMA
Jones Keith Anthony purchased 30,000 shares of Humacyte, Inc. (HUMA) at $0.59 on 2026-08-17.
HUMA sentiment & insider activity
Recent HUMA coverage spans technology, insider activity and earnings.
In the last 30 days, HUMA insiders filed 2 SEC Form 4 transactions — 2 purchases ($25K) and no sales. The most active reporter was Jones Keith Anthony with 2 filings.
What's driving HUMA
Small insider purchase may signal confidence but limited market impact due to modest size.
Favorable trial results could enhance commercialization prospects.
Small insider purchase may signal positive sentiment but size is modest.
Positive trial data may boost HUMA stock and attract partnership interest.
Earnings reveal higher revenue but continued large losses; cash runway supports upcoming trials and filing, suggesting near‑term volatility.
alphai scores every news story that mentions HUMA with an AI model for sentiment and relevance, and aggregates insider trades from Humacyte, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $HUMA
Score
Jones Keith Anthony purchased $7K of HUMA
Jones Keith Anthony purchased 10,000 shares of Humacyte, Inc. (HUMA) at $0.69 on 2026-08-20.
1 min readWeekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks
Ultragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
3 min readJones Keith Anthony purchased $18K of HUMA
Jones Keith Anthony purchased 30,000 shares of Humacyte, Inc. (HUMA) at $0.59 on 2026-08-17.
1 min readHumacyte's Bioengineered Vessel Shows Phase 3 Success In Hemodialysis Access Trial
Humacyte (HUMA) reported one-year results from its Phase 3 trial in The Lancet Digital Health, showing its bioengineered vessel (ATEV) outperformed standard AV fistulas in hemodialysis patients, especially high-risk groups. The company aims to advance ATEV for broader use. HUMA stock closed at $0.58, up 3.76%, and was at $0.59 in pre-market trading.
1 min read
Humacyte (HUMA) Q2 2026 Earnings Call Transcript
Humacyte (HUMA) reported Q2 2026 product revenue of $0.4M, up from $0.1M, driven by Symvess launch. V012 Phase III trial met primary endpoint, showing 91 more catheter-free days for ATEV vs. AV fistula. Company targets Nov. 2026 sBLA filing for dialysis access, with potential 2027 launch. Cash position is $80.3M post-June equity offering. Net loss was $36.8M, with $54.4M loss for H1 2026. Management noted slower-than-expected trauma market adoption and reimbursement pressures.
3 min readHumacyte publishes Phase 3 trial results in Lancet journal
Humacyte Inc. (HUMA) published one-year Phase 3 trial results in The Lancet, showing its ATEV outperformed traditional methods for hemodialysis access in end-stage kidney disease patients. The study highlighted benefits for high-risk groups. The company plans to submit a supplemental BLA in 2H 2026 to expand Symvess's label.
2 min readHumacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results
Humacyte announced the publication of its V007 Phase 3 trial results in Lancet Digital Health. The trial focused on hemodialysis access. The company claims positive outcomes, which may impact its valuation.
1 min readA bioengineered vessel beat fistulas for women and men with obesity and diabetes on dialysis
Humacyte (HUMA) published one-year Phase 3 trial results in The Lancet Digital Health, showing its acellular tissue engineered vessel (ATEV) outperformed autogenous AV fistula in hemodialysis patients, especially women and men with obesity/diabetes. The company plans to submit an sBLA in H2 2026 for a second AV access indication. HUMA stock rose 21.20% on the news.
2 min read
Humacyte, Inc. Q2 2026 Earnings Call Summary
Humacyte reported Q2 2026 updates on Symvess uptake and pipeline progress. Management cited slower adoption due to underestimated education needs and rebuilt its sales team. Phase III V012 in female dialysis patients showed 91 more catheter-free days vs standard of care. Humacyte plans an sBLA filing for dialysis in Nov 2026, targeting PDUFA May 2027. Cash was $80.1M at June 30, 2026.
6 min readHumacyte's ATEV Outperforms AV Fistula; Dialysis Access SBLA Planned For 2H26
Humacyte (HUMA) reported Q2 2026 results and interim Phase 3 V012 data for ATEV in female dialysis patients. ATEV delivered 91 more catheter-free days than AV fistula and had fewer infections (6 vs 23 per 100 patient-years). Humacyte plans an FDA sBLA filing for dialysis access in 2H26. Cash was $80.3M; Q2 net loss was $36.8M.
6 min read